Acepodia (6976.TWO)

Executive Summary

Acepodia is a clinical-stage biotechnology company pioneering off-the-shelf cell therapies for cancer and autoimmune diseases. Its core innovation is the Antibody-Cell Conjugation (ACC) platform, which leverages Nobel Prize-winning click chemistry to attach tumor-targeting antibodies directly to immune cells, eliminating the need for genetic engineering. This approach enables scalable, cost-effective production of allogeneic cell therapies with enhanced targeting specificity and reduced manufacturing complexity. The company's lead programs include ACE-201 targeting CD20 for B-cell malignancies and ACE-501 targeting HER2 for solid tumors, both in Phase 1 clinical trials. Acepodia is also exploring indications in autoimmune disorders, leveraging its platform to address a broad range of diseases. With its novel technology and strategic positioning in the rapidly growing cell therapy market, Acepodia aims to deliver accessible, off-the-shelf treatments to patients.

Upcoming Catalysts (preview)

• Q4 2026Interim Phase 1 data for ACE-201 in B-cell malignancies65% success
• H1 2027Initiation of Phase 1b/2 trial for ACE-501 in HER2+ solid tumors60% success
• 2026Potential partnership or licensing deal for ACC platform in autoimmune indications50% success